RE:RE:sellingYaz, keep flappin those rotten gums of yours, making three bucks a post telling half truths, deceit and lies. You were wrong on so many things!!!! NO PP, YAZ. Certainty is coming, and its in the form of a jv, not a pp, like you and the choir wanted, boy!!
NO SIGN OF PROGRESSION OF THE DiSEASE, STOPPED IN ITS TRACKS OVER 180 DAYS, YAZ, IN BLACK AND WHITE!! HOW YOU GOING TO SPIN THAT, YAZ???? CANT SPIN THE AMAZING TRUTH, 4 FOR 4, EVERYONE DONE HAD THEIR CANCER PROGRESSION STOPPED WITH ONE TREATMENT, WHAT OTHER PHARMA STOPPED PROGRESSION of CANCER WITh ONE TREATMENT?????? ??????????????????? Yaz, from Nov 8. Nr.. that you love to refer to!!!! What other phama had these results after one treatment?? You have never given us one example!!! Scummie, not one example!!!! Keep shooting your mouth off telling lies!
Answer the question?? Show us one pharma with better phase one results after one treatment????????
No sign of progression of the disease at 180 day result.
- ""Patients one and two have a previous history of Upper Urinary Tract Urothelial Carcinoma diagnosed prior to their PDT treatment, while patients 3 and 4 are at high risk of UUTUC. This clinical observation, along with peer-reviewed clinical research, raises the possibility that the source of patient one, two and threes recurrent NMIBC may have originated by seeding in the bladder from these extravesical sites, potentially confounding the exploratory outcomes for these patients (In this NMIBC patient population, 80% of patients recur, while 50% of patients progress). The extravesical upper tract locations of all treated patients were not exposed to the PDT treatment in the Study.
- Although patient one, two and three, treated at the MRSD (1/2 of Therapeutic Dose), recurred at 180 days post treatment, there was no sign of progression of the disease; indicating, that they may benefit from multiple PDT treatments, delivered between 90 to 180 days post treatment.
The interim data obtained to date suggests that the Theralase PDT treatment was able to achieve the primary, secondary and exploratory objectives of the Study at both the MRSD and Therapeutic Dose, delaying recurrence and more importantly delaying progression of NMIBC, for more than 90 days post PDT treatment, which would be of particular benefit for NMIBC patients; especially, patients who do not have a previous history of UUTUC.
Read more at https://www.stockhouse.com/news/press-releases/2017/11/08/theralase-provides-interim-data-analysis-on-anti-cancer-treatmen.
Damn , people, has another pharma treated a patient once, and a <span style="background-color:#00ff00;">100% of the patients had their progression stopped for over 180 days. Any one pharma do that? Only one, TLT!!!!
bionicjoe wrote: patience69 wrote: Cant see anyone selling unless it is for optics. We are on the verge of a couple of major news events. Financing & new patients treated. The market hates uncertainty. When these mysteries are cleared up we will be on the launch pad
There's no uncertainty as far as the market is concerned. In the Nov 8 PR update the company failed to give the market any early insight into the treatment being capable of eventually qualifying as a new standard of care in the treatment of bladder cancer. Based on years of pre-clinical rat models that the company fed the market and the pumping job done on this board, it plain and simply should have worked. It didn't manage to stop cancer recurrence for the short 6 month life of this trial. Shareholders and management can try to work around that glaring issue all they want but until its settled investors will believe the worst. They have the 6 month data on the 4th patient so why don't they release it with a cautionary note that it's just 1 sample if the patient remained cancer free? This is a case where silence is not golden.
BTW, I doubt announcing the remaining patients have been treated will result in anything other than a penny or two jump in the sp. The market is looking for something more substantial than procedural news.